Please Wait
Applying Filters...
menu
    • menu
    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Menu

    Cebranopadol

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 269,920Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Tris Pharma to Present Positive Results of Cebranopadol Study
    Tris Pharma to Present Positive Results of Cebranopadol Study

    12 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250612665724/en/Tris-Pharma-to-Debut-Positive-Results-of-Intranasal-Snorting-Human-Abuse-Potential-Study-of-Cebranopadol-an-Investigational-First-In-Class-Oral-Dual-NMR-Agonist-for-the-Treatment-of-Moderate-to-Severe-Pain-at-the-2025-CPDD-Annual-Meeting

    BUSINESSWIRE
    12 Jun 2025
    Share Share
    Tris Pharma to Present Positive Phase 3 Results for Cebranopadol
    Tris Pharma to Present Positive Phase 3 Results for Cebranopadol

    01 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250501204234/en/Tris-Pharma-to-Unveil-Positive-Phase-3-Results-including-a-Strong-Safety-Profile-Showcasing-the-Potential-of-Cebranopadol-an-Investigational-First-in-Class-Dual-NMR-Agonist-for-the-Treatment-of-Pain-at-the-2025-ASRA-Annual-Meeting

    BUSINESSWIRE
    01 May 2025
    Share Share
    Tris Pharma to Present New Data at AAPM PainConnect Annual Meeting
    Tris Pharma to Present New Data at AAPM PainConnect Annual Meeting

    01 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250401157017/en/Tris-Pharma-to-Present-New-Data-at-AAPM-PainConnect-Annual-Meeting-and-Showcase-Potential-of-Cebranopadol-a-First-in-Class-Investigational-Dual-NMR-Agonist-for-the-Treatment-of-Pain

    BUSINESSWIRE
    01 Apr 2025
    Share Share
    Tris Reports Positive Ph3 Alleviate-2 Data For Cebranopadol
    Tris Reports Positive Ph3 Alleviate-2 Data For Cebranopadol

    06 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250306271136/en

    BUSINESSWIRE
    06 Mar 2025
    Share Share
    Tris shows its opioid alternative is less likely to be abused
    Tris shows its opioid alternative is less likely to be abused

    28 Jan 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/tris-builds-clinical-case-opioid-alternative-showing-pain-drug-less-likely-be-abused

    FIERCE BIOTECH
    28 Jan 2025
    Share Share
    Tris Pharma's Cebranopadol Shows Prolonged Pain Relief at PAINWeek 2024
    Tris Pharma's Cebranopadol Shows Prolonged Pain Relief at PAINWeek 2024

    03 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240903523518/en

    BUSINESSWIRE
    03 Sep 2024
    Share Share